Regeneron beats quarterly estimates on eczema drug demand; launches dividend program
(Reuters) - Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, ...
Read moreDetails
